The Type B portion of the Phase 1 EQUALISE study investigating itolizumab for the treatment of lupus nephritis (LN) (lupus-related kidney disease) has announced encouraging data.

When added to mycophenolate mofetil/mycophenolic acid (MMF/MPA) and corticosteroids treatment, itolizumab reduced urine protein creatinine (UPC) levels in study participants. High UPC levels are indicative of kidney dysfunction and serve as a biomarker for LN. There are 17 participants in the study; 16 of which exhibited a complete or partial response through week 36 of therapy. 

Continue to follow the Lupus Foundation of America for updates on itolizumab and other lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.

Read the announcement